argenx (ARGX) Reports ADDRESS Study of Efgartigimod SC Did Not Achieve Statistical Significance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
These 6 stocks are new Top Picks at Jefferies
December 20, 2023 3:51 PM ESTJefferies' Franchise Picks represent their analysts most confident, Buy-rated stocks within the research companys US Research portfolio. These top selections are backed by thorough analysis, distinct factors, and favorable valuations indicating potential for growth.
This month, Jefferies added 6 new ideas to the list.
argenx SE
argenx (NASDAQ: ARGX) was added to the list as Jefferies analysts consider the biotechnology companys s lead asset, Vyvgart, to be a best-in-class drug owing to its potent IgG drops, clean safety profile without dose-limiting albumin drops or effector-related adverse events, and convenient... More
Immunovant (IMVT) Trades Lower in Sympathy with argenx (ARGX)
December 20, 2023 7:40 AM ESTImmunovant (NASDAQ: IMVT) Trades Lower in Sympathy with argenx (NASDAQ: ARGX)
ARGX down 23% after ADDRESS study did not meet primary or secondary endpointsargenx SE (Euronext & Nasdaq: ARGX) announced topline results from the ADDRESS study... Moreargenx SE (ARGX) Defended at Stifel
December 20, 2023 6:17 AM ESTStifel analyst Derek Archilia reiterated a Buy rating and $560.00 price target on argenx SE (NASDAQ: ARGX)
The analyst comments "The failure of efgartigimod in Pemphigus comes as quite a surprise to us. Even on the heels of the recent failure in ITP, we... More
Deutsche Bank Issues Mea Culpa, Downgrades argenx SE (ARGX:BB) (ARGX) to Hold
December 20, 2023 4:44 AM ESTDeutsche Bank analyst Emmanuel Papadakis downgraded argenx SE (ARGX:BB) (NASDAQ: ARGX) from Buy to Hold with a price target of EUR375.00 (from EUR500.00).
The analyst comments "ARGX today announced headline results for the next major clinical read out in the Vyvgart line-extension... More
